Table 1 Demographic, clinical and bacteriological data of 46 individuals analyzed and association between demographic, clinical and bacteriological data in the outcome of 31 patients with MSIs.
Parameter | No. (%) of individuals analyzed | No. (%) of patients with MSI | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
(N = 46) | (N = 31) | |||||||||
Overall | colonized | MSI | P value | cure | recurrence | P value | OR | IC 95% | P value | |
(N = 15) | (N = 31) | (N = 16) | (N = 15) | |||||||
Demographic data | ||||||||||
Age (SD)* | 43.39 ± 17.76 | 33.67 ± 12.36 | 48.10 ± 18.21 | 0.015 | 41.56 ± 18.60 | 55.07 ± 15.47 | 0.058 | 1.056 | 0.998–1.119 | 0.061 |
Male n.(%) | 28 (60.9) | 4 (8.7) | 24 (52.2) | < 0.001 | 14 (45.1) | 10 (32.2) | 0.220 | |||
Female n.(%) | 18 (39.13) | 11 (23.9) | 7 (15.2) | 2 (12.5) | 5 (16.1) | |||||
Health status | ||||||||||
Obesity (IMC > 26) | 11 (23.9) | 3 (6.5) | 8 (17.4) | > 0.999 | 4 (12.9) | 4 (12.9) | > 0.999 | |||
Smoking | 9 (19.6) | 1 (2.2) | 8 (17.4) | 0.235 | 3 (9.7) | 5 (16.1) | 0.433 | |||
Diabetes | 7 (15.2) | 0 | 7 (15.2) | 0.078 | 5 (16.1) | 2 (6.4) | 0.394 | |||
Immunosuppression | 8 (17.3) | 0 | 8 (17.4) | 0.040 | 4 (12.9) | 4 (12.9) | > 0.999 | |||
Infection characteristics | ||||||||||
Fracture-related infection | 16 (57.14) | 11 (84.62) | 5 (33.3) | 0.009 | ||||||
No fracture | 15 (48.3) | 5 (16.1) | 10 (66.7) | |||||||
No. Multiple revisions | ||||||||||
Up to 1 review (0–1) | 13 (41.9) | 8 (25.8) | 5 (16.1) | 0.347 | ||||||
Two or more revisions | 26 (83.9) | 8 (25.8) | 10 | |||||||
Antimicrobial resistance | ||||||||||
Multidrug resistance | 10 (62.5) | 12 (80.0) | 0.433 | |||||||
Methicillin | 30 (65.2) | 6 (13.0) | 24 (52.1) | 0.012 | 10 (32.3) | 14 (45.1) | 0.040 | |||
Gentamicin | 19 (41,3) | 3 (6.5) | 16 (34.8) | 0.041 | 7 (22.6) | 9 (29.0) | 0.365 | |||
Ciprofloxacin | 23 (50.0) | 3 (6.5) | 20 (45.5) | 0.004 | 9 (29.0) | 11 (35.5) | 0.320 | |||
Erythromycin | 28 (60.9) | 10 (21.7) | 18 (39.1) | 0.575 | 9 (29.0) | 9 (29.0) | 0.832 | |||
Rifampicin | 12 (26.0) | 0 | 12 (26.0) | 0.004 | 5 (16.1) | 7 (22.6) | 0.378 | |||
Vancomycin | 0 | 0 | 0 | > 0.999 | 0 | 0 | ||||
Linezolid | 0 | 0 | 0 | > 0.999 | 0 | 0 | ||||
Virulence | ||||||||||
Biofilm formation | ||||||||||
Strong/moderate | 34 (74.0) | 9 (19.6) | 25 (54.3) | 0.040 | 11 (35.5) | 14 (45.1) | ||||
Weak biofilm | 6 (19.3) | 1 (3,2) | 0.083 | 0.070 | 0.005–0.979 | 0.048 | ||||
ica operon (ADBC) | 27 (58.7) | 9 (19.6) | 18 (39.1) | 0.901 | 8 (25.8) | 10 (32.2) | 0.347 | |||
IS 256 | 19 (41.3) | 0 | 19 (41.4) | < 0.001 | 7 (22.6) | 12 (38.7) | 0.038 | 8.002 | 1062–60.315 | 0.044 |
